Evidence map›Paper›PMID 33991178›Full record

Trial reportESC heart failure2021

Eligibility of outpatients with chronic heart failure for sodium-glucose co-transporter-2 inhibitors.

Gianmarco Angelini, Miriam Albanese, Raffaella Ursi, Francesco Lisi, Maria Consiglia Bellino, Luca Amato, Margherita Ilaria Gioia, Giuseppe Parisi, Natale Daniele Brunetti, Giuseppina Piazzolla and 2 more

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gianmarco AngeliniSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Miriam AlbaneseSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Raffaella UrsiSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Francesco LisiSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Maria Consiglia BellinoSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Luca AmatoSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Margherita Ilaria GioiaCardiology Unit, Hospital of Brindisi, S.S. 7 per Mesagne, Brindisi, 72100, Italy.
Giuseppe ParisiCardiology Department, Local Health Service of Bari, Bari, Italy.
Natale Daniele BrunettiDepartment of Medical and Surgical Science, University of Foggia, Viale Luigi Pinto 1, Foggia, 71122, Italy.
Giuseppina PiazzollaInterdisciplinary Department of Medicine, Internal Medicine Unit, University of Bari, Bari, 70124, Italy.
Marco Matteo CicconeSchool of Cardiology, University of Bari, Piazza Giulio Cesare 11, Bari, 70124, Italy.
Massimo IacovielloDepartment of Medical and Surgical Science, University of Foggia, Viale Luigi Pinto 1, Foggia, 71122, Italy.
University of Bari Aldo Moro · ITUniversity of Foggia · ITOspedale A. Perrino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsSodium-glucose co-transporter-2 inhibitors (SGLT2i) have been shown to have a relevant role in the prevention of hospitalizations for heart failure and improvement in the life expectancy of patients with diabetes and outpatients with chronic heart failure (CHF) with reduced left ventricular ejection fraction, independently from the presence of type 2 diabetes mellitus (T2DM). The aim of our study was to evaluate in a real-world population the number of outpatients with CHF who meet the enrolment criteria of the main randomized controlled trials (RCT) published in the last 5 years and consequently identify the percentage of patients who could potential benefit from SGLT2i therapy. METHODS AND

resultsWe retrospectively evaluated all consecutive outpatients referred for CHF. The diagnosis of T2DM was according to the latest European Society of Cardiology Guidelines. Clinical characteristics considered for the enrolment in the RCTs were recorded. We enrolled 515 patients, 384 (75%) of whom had a left ventricular ejection fraction (LVEF) ≤ 40%, 82 (16%) had pre-diabetes, and 187 (36%) had diabetes. Most of the patients with LVEF ≤ 40% met the criteria for the DAPA-HF trial (65%), and this percentage was even higher if the serum level of N-terminal pro-brain natriuretic peptide was not considered. A high percentage of patients with diabetes and LVEF > 40% met the criteria for the DECLARE (39%), CANVAS (47%), and EMPA-REG (30%) trials. Patients meeting the enrolment criteria of RCTs evaluating SGLT2i were also characterized by a high risk of heart failure events during follow-up.

conclusionsIn spite of a low number of patients actually treated with SGLT2i, we observed that a high prevalence of patients with CHF met the clinical characteristics of RCTs that have demonstrated a beneficial effect of SGLT2i.

Indexed as

Heart FailureSodium-Glucose Transporter 2 InhibitorsSymportersGlucoseHumansOutpatientsSodiumGlucoseSodiumSodium-Glucose Transporter 2 InhibitorsSymportersHeart failureSodium-glucose co-transporter inhibitorTherapyType 2 diabetes mellitus

Identifiers

PMID33991178
PMCPMC8318395
OpenAlexW3162562013

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.